Going forward..., page-29

First 29 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

22/09/18

18:12

Post #: 35775710
Share

Originally posted by smarty13 ↑

We all want a higher share price an I for one have other goals I need to achieve at Xmas an no I will have to sell shares to achieve so the higher the price the better for me

But I am extremely happy with the way we are heading and this why

We have shown fantastic lab results across multiple fields asthma, cardio vas etc

We have outstanding universities across the world utilising our cymerus platform for research

This all means if there was a takeover these factors will come into our price tag

We have a major insto on our books along with a top 200 in the world company Fuji

And the big one we haven’t yet set a true bench mark for the price of our product which I really like ! We didn’t really know how good our product is now we do ! Now we can come to the table with facts proof and demand what we want not ask our partners to float there money on a lab result like we had with Fuji (double digit royalties ??) we are now setup to offer stage 2 trials a proven product and a massive advantage to anyone who wants to be a leader in this field.
We have only just gotten to this point where we are in the controlling spot of any negotiation so give a few months fellas this is big dollars here no need to rush for a deal but ensure it’s the best deal even though personally I wish they would hurry up JMT

Expand

All very wonderful and why we're in this business...

So Smarty, what's holding things back?
Why are we 37c off all time highs?

Any insights?

Last edited by Sector: 22/09/18

CYP Price at posting: $1.21 Sentiment: Buy Disclosure: Held
6 Upvote

1 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 2,102 more messages in this thread...

First 29 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 27.0¢		Change 0.000(0.00%)		Mkt cap ! $48.78M

Open	High	Low	Value	Volume
28.0¢	28.0¢	27.0¢	$44.86K	165.2K

Buyers (Bids)

No.	Vol.	Price($)
2	24189	27.0¢

Sellers (Offers)

Price($)	Vol.	No.
28.0¢	10983	1

View Market Depth

No.	Vol.	Price($)
2	24189	0.270
2	10000	0.265
2	105000	0.260
2	10800	0.250
1	10000	0.245

Price($)	Vol.	No.
0.280	10983	1
0.290	49421	2
0.295	25028	2
0.300	72500	2
0.305	29140	1

Last trade - 16.10pm 07/10/2024 (20 minute delay)

CYP (ASX) Chart

Going forward..., page-29

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Going forward..., page-29

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News